Jayasuriya Anula
SEC insider (Form 3/4/5 filer). CIK 0001822933. Director at Lineage Cell Therapeutics, Inc. (LCTX) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Jul 1, 2026. Located in CARLSBAD, CA.
Companies Jayasuriya Anula has filed insider reports for
- Lineage Cell Therapeutics, Inc. (LCTX): Director
- Jaguar Health, Inc. (JAGX): Director
Jayasuriya Anula
CIK: 0001822933
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jul 1, 2026LCTX
Lineage Cell Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
125K shares- - Dec 11, 2025JAGX
Jaguar Health, Inc.
AwardDirect5.9K shares- - Jul 1, 2025LCTX
Lineage Cell Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
75K shares- - Oct 8, 2024JAGX
Jaguar Health, Inc.
AwardDirectStock option (right to buy)
21K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 1, 2026 |  LCTX Lineage Cell Therapeutics, Inc. | Award Stock Option (Right to Buy) | 125,000 | - | - | Direct |
| Dec 11, 2025 |  JAGX Jaguar Health, Inc. | Award | 5,870 | - | - | Direct |
| Jul 1, 2025 | LCTX Lineage Cell Therapeutics, Inc. | Award Stock Option (Right to Buy) | 75,000 | - | - | Direct |
| Oct 8, 2024 | JAGX Jaguar Health, Inc. | Award Stock option (right to buy) | 21,000 | - | - | Direct |
1-4 of 4 transactions